On a spree, Astel­las bags a next-gen, Park­er-backed CAR-T plat­form with $665M buy­out deal

A lit­tle more than a year af­ter the Park­er In­sti­tute swooped in with an eq­ui­ty in­vest­ment for South San Fran­cis­co-based Xyphos Bio­sciences’ sec­ond-gen CAR-T plat­form, Astel­las has stepped in with a $665 mil­lion deal to buy the whole thing.

Tokyo-based Astel­las — which an­ted up $120 mil­lion in cash to close the deal — was at­tract­ed to a bis­pe­cif­ic ap­proach that promis­es to be both safer and more ef­fec­tive than the pi­o­neers now on the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.